Filed pursuant to Rule 424(b)(3)
Registration No. 333-281079
![](https://www.sec.gov/Archives/edgar/data/1141284/000121390024066145/image_001.jpg)
Actelis
Networks, Inc.
2,069,317
Shares of Common Stock
This
prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus, or the selling stockholders,
of up to 2,069,317 shares of our common stock, par value $0.0001 per share, issuable upon the exercise of warrants, as further described
below under “Prospectus Summary — Recent Developments — July 2024 Warrant Inducement.”
We
are not selling any common stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of
shares by any of the selling stockholders, however, we will receive proceeds from the exercise of any Warrants for cash.
The
selling stockholders or its transferees, pledgees, assignees, or successors-in-interest may offer and sell or otherwise dispose of the
shares of common stock described in this prospectus from time to time through public or private transactions at prevailing market prices,
at prices related to prevailing market prices or at privately negotiated prices. The selling stockholder will bear all commissions and
discounts, if any, attributable to the sales of shares. We will bear all other costs, expenses, and fees in connection with the registration
of the shares. See “Plan of Distribution” beginning on page 15 for more information about how a selling stockholder may sell
or dispose of the shares of Common Stock.
Our common stock is traded on the Nasdaq Capital Market under the symbol
“ASNS.” On August 6, 2024, the closing price of our common stock on the Nasdaq Capital Market was $1.32 per share.
Investing
in our securities involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well
as the information incorporated herein and therein by reference carefully before you make your investment decision. See “Risk Factors”
beginning on page 5 of this prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is August 7, 2024.
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”). The
selling stockholders named in this prospectus may from time to time sell the securities described in the prospectus. You should read
this prospectus together with the more detailed information regarding our company, our Common stock, and our financial statements and
notes to those statements that appear elsewhere in this prospectus and any applicable prospectus supplement together with the additional
information that we incorporate in this prospectus by reference, which we describe under the heading “Where You Can Find More Information.”
You
should rely only on the information contained in, or incorporated by reference in, this prospectus and in any accompanying prospectus
supplement. We have not authorized anyone to provide you with different information from that contained in, or incorporated by reference
in, this prospectus. You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any
date other than the date on the front of those documents or that any document incorporated by reference is accurate as of any date other
than its filing date. You should not consider this prospectus to be an offer or solicitation relating to the securities in any jurisdiction
in which such an offer or solicitation relating to the securities is not authorized. Furthermore, you should not consider this prospectus
to be an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified to do so, or
if it is unlawful for you to receive such an offer or solicitation.
In
this prospectus, we frequently use the terms “we,” “our,” “us,” “our company,” and the
“Company” to refer to Actelis Networks, Inc.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the documents incorporated by reference herein contain certain “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act”).
We have tried, whenever possible, to identify these forward-looking statements using words such as “may,” “will,”
“expect,” “believe,” “estimate,” “anticipate,” “intend,” “continue,”
“plan,” “predict,” “seek,” “should,” “would,” “could,” “potential,”
“ongoing,” and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These
statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements
involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to
differ materially from those expressed in, or implied by, such statements. Forward-looking statements contained herein include, but are
not limited to, statements about:
|
● |
our
history of losses and need for additional capital to fund our operations and our ability to obtain additional capital on acceptable
terms, or at all; |
|
● |
our
ability to protect our intellectual property and continue to innovate; |
|
● |
our
success in retaining or recruiting, or changes required in, our officers, key employees or directors; |
|
● |
the
potential insufficiency of our disclosure controls and procedures to detect errors or acts of fraud; |
|
● |
the
accuracy of our estimates regarding expenses, future revenues, and capital requirements; |
|
● |
the
success of competing products or technologies that are or may become available; |
|
● |
our
ability to grow the business due to the uncertainty resulting from the COVID-19 pandemic or any future pandemic; |
|
● |
our
ability to comply with complex and increasing regulations by governmental authorities; |
|
● |
our
ability to regain and maintain compliance with continued listing requirements of the Nasdaq Capital Market; |
|
● |
our
ability to continue as a going concern; |
|
● |
statements
as to the impact of the political and security situations in Israel on our business, including due to the number of armed conflicts
between Israel and Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia and political
group in Lebanon); |
|
● |
our
public securities’ potential liquidity and trading; and |
|
● |
our
expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act. |
Forward-looking
statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the
industry in which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development
and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all
of our forward-looking statements herein may turn out to be inaccurate. Important factors that may cause actual results to differ materially
from current expectations include, among other things, those listed under “Risk Factors,” Use of Discussion and Analysis
of Financial Condition and Results of Operations,” “Business” and elsewhere herein or by incorporation by reference.
Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. You should read thoroughly
this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different
from and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.
The
forward-looking statements included in this prospectus speak only as of the date of this prospectus. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance
and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we
assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in
the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC
after the date of this prospectus. See “Where You Can Find More Information.”
On
April 19, 2023, we effected a reverse stock split of our shares of common stock at the ratio of 1-for-10. Unless indicated otherwise
by the context, all common stock, option, warrant and per share amounts, as well as share prices appearing in this prospectus have been
adjusted to give retroactive effect to the stock split for all periods presented.
PROSPECTUS
SUMMARY
This
summary highlights information contained elsewhere in this prospectus. Because this is only a summary, it does not contain all of the
information that may be important to you. You should read this entire prospectus and should consider, among other things, the matters
set forth under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
and our consolidated financial statements and related notes thereto appearing elsewhere in this prospectus before making your investment
decision. This prospectus contains forward-looking statements and information relating to Actelis Networks, Inc. See “Cautionary
Note Regarding Forward-Looking Statements” on page iii.
Actelis
Networks, Inc. (“we”, “the Company”, “Actelis”, “us”, “our”) is a market
leader in cyber-hardened, rapid-deployment networking solutions for wide-area IoT applications including federal, state and local government,
intelligent traffic systems (“ITS”), military, utility, rail, telecom and campus applications. Our unique portfolio of hybrid
fiber, environmentally hardened aggregation switches, high density Ethernet devices, advanced management software and cyber-protection
capabilities, unlocks the hidden value of essential networks, delivering safer connectivity for rapid, cost-effective deployment.
Our
networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines which our patented
technology can upgrade to Fiber-grade to jointly create what we believe to be a highly cost-effective, secure, and quick-to-deploy network.
Our patent protected hybrid fiber networking solutions deliver excellent communication over fiber to locations that may be easy to reach
with new fiber. However, for locations that are difficult, or too costly to reach with fiber, we can upgrade existing copper lines to
deliver cyber-hardened, high-speed connectivity without needing to replace the existing copper infrastructure with new fiber. We believe
that such hybrid fiber copper networking solution has distinct advantages in most real-life installations, while providing significant
budget savings and accelerating deployment of modern IoT networks, as based on our experience, most IoT projects have challenging,
hard to reach with fiber locations which may explode such projects’ timeline and budgets. We believe that our solutions can provide
connectivity over either fiber or copper with speeds of up to multi-Gigabit communication, while supporting Fiber-grade reliability and
quality.
A
primary focus of ours is to provide our customers with a cyber-secure network solution. We currently offer Triple-Shield protection of
data delivered with coding, scrambling and encryption of the network traffic. We also provide secure, encrypted access to our network
management software, and are working to further enhance system-level and device-level software protection. We are also working to introduce
additional capabilities for network-wide cyber protection software as an additional SW and license-based services.
When
high speed, long reach, reliable and secure connectivity is required, network operators usually resort to using wireline communication
over physical communication lines such as fiber, coax, and copper, rather than wireless communication that is more limited in performance,
reliability, reach and security. However, new fiber wireline infrastructure is costly to deploy, involves lengthy civil works to install,
and, based on our internal calculations, often accounts for more than 50% of total cost of ownership (ToC) and time to deploy wide-area
IoT projects.
Providing
new fiber connectivity to hard-to-reach locations is especially costly and time-consuming, often requiring permits for boring, trenching,
and right-of-way, sometimes done over many miles. Connecting such hard-to-reach locations may cause significant delays and budget overruns
in IoT projects. Our solutions aim to solve these challenges by instantly enhancing performance of such existing copper and coax infrastructure
to fiber-grade performance, through the use of advanced signal processing and unique, patented network architecture, without the need
to run new fiber to hard-to-reach locations; thus, effectively accelerating deployment of many IoT projects, as we estimate, sometimes
from many months to only days. The result for the network owner is a hybrid network that optimizes the use of both new Fiber
(where available) as well as upgraded, fiber-grade copper and coax that is now modernized, digitized and cyber-hardened. This unique
hybrid network approach is making IoT projects often significantly more affordable, fast to deploy and predictable to plan and budget.
In
addition, our solutions can also provide power over existing copper and coax lines to remotely power up network elements and IoT components
connected to them (like cameras, small cell and Wi-Fi base stations sensors etc.). Connecting power lines to millions of IoT locations
can be costly and very time consuming as well (similar to data connectivity, for the same reason — need for civil works).
By offering the ability to combine power delivery over the same existing copper and coax lines that we use for high-speed data, we believe
our solutions are solving yet another important challenge in connecting hard-to-reach locations. We believe that combining communication
and power over the same existing lines is particularly important to help connect many fifth generation, or 5G, small cells and Wi-Fi
base stations, as high cost of connectivity and power is often slowing their deployment.
Since
our inception, our business has been focused on serving telecommunication service providers, also known as Telcos, to provide connectivity
for enterprises and residential customers. Our products and solutions have been deployed with more than 100 telecommunication service
providers worldwide, in enterprise, residential and mobile base station connectivity applications. In recent years, as we have further
developed our technology and introduced additional products, we turned our focus on serving the wide-area IoT markets. Our operations
are focused on our fast-growing IoT business, while maintaining our commitment to our existing Telco customers. In 2023, we introduced
new product offerings, some of which could serve both the IoT markets and our Telco customers.
Recent
Developments
June
2024 Warrant Inducement
On
June 5, 2024, we entered into an inducement agreement with a certain holder of certain of our existing warrants to purchase up to an
aggregate of 999,670 shares of our common stock originally issued on May 8, 2023, with a five and one-half year term, at an exercise
price of $2.75 per share (the “May 2023 Warrants”).
Pursuant
to the inducement agreement, the holder agreed to exercise for cash its May 2023 Warrants to purchase an aggregate of 999,670 shares
of our common stock at an exercise price of $2.75 per share, in consideration of our agreement to issue new common stock purchase warrants
(the “June 2024 Warrants”), as described below, to purchase up to an aggregate of 1,999,340 shares of our common stock, at
an exercise price of $2.00 per share.
H.C.
Wainwright & Co., LLC (the “Placement Agent”) acted as our exclusive placement agent in connection with the June 2024
Warrant Inducement. In connection with the June 2024 Warrant Inducement, we issued to certain designees of the Placement Agent warrants
(the “June 2024 Placement Agent Warrants”) to purchase up to 69,977 shares of common stock (representing 7.0% of the Existing
Warrants being exercised), which have the same terms as the June 2024 Warrants, except that the Placement Agent Warrants have an exercise
price equal to $3.4375 per share (125% of the exercise price of the May 2023 Warrants). The June 2024 Warrants were immediately exercisable
from the date of issuance, until five and one-half year anniversary of such date for 999,670 of the June 2024 Warrants, and until twenty
four months anniversary of such date for the remaining 999,670 of the June 2024 Warrants. The Placement Agent Warrants are immediately
exercisable from the date of issuance, until the five and one-half year anniversary of such date.
The
closing of the June 2024 Warrant Inducement occurred on June 6, 2024.
July
2024 Warrant Inducement
On
June 30, 2024, we entered into an inducement letter with a holder of our June 2024 Warrants, to purchase up to an aggregate of 999,670
shares of the June 2024 Warrants, originally issued on June 6, 2024, with a twenty-four month term,
at an exercise price of $2.00 per share.
Pursuant
to the inducement letter, the holder agreed to exercise for cash its warrants to purchase an aggregate of 999,670 shares of our common
stock at an exercise price of $2.00 per share, in consideration of our agreement to issue new common stock purchase warrants (the “July
2024 Warrants”), as descried below, to purchase up to an aggregate of 1,999,340 shares of our common stock (the
“July 2024 Warrant Shares”), at an exercise price of $1.75 per share.
We
engaged the Placement Agent to act as our exclusive placement agent in connection with the July 2024 Warrant Inducement. In connection
with the July 2024 Warrant Inducement, we issued to
certain designees of the Placement Agent warrants (the “July 2024 Placement Agent Warrants”) to purchase up to 69,977 shares
of common stock (representing 7.0% of the Existing Warrants being exercised), which have the same terms as the July 2024 Warrants, except
that the Placement Agent Warrants have an exercise price equal to $2.50 per share (125% of the exercise price of the June 2024 Warrants).
The July 2024 Warrants were immediately exercisable from the date of issuance, until twenty four months anniversary of such date. The
July 2024 Placement Agent Warrants are immediately exercisable from the date of issuance, until the five and one-half year anniversary
of such date.
The closing of the July 2024 Warrant Inducement occurred on July 2,
2024. We also agreed to file this registration statement, providing for the resale of the New Warrant Shares issued or issuable upon the
exercise of the New Warrants (the “Resale Registration Statement”) as soon as practicable after the Closing Date (and in any
event within thirty (30) calendar days of the date of the Inducement Letter), and to use commercially reasonable efforts to have such
Resale Registration Statement declared effective by the SEC within sixty (60) calendar days following the date of the Inducement Letter
(or within ninety (90) calendar days following the date of the Inducement Letter in case of “full review” of the Resale Registration
Statement by the SEC) and to keep the Resale Registration Statement effective at all times until no holder of the July 2024 Warrants owns
any July 2024 Warrants or July 2024 Warrant Shares.
Nasdaq
Listing Compliance
On
August 25, 2023, we received a notification letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock
Market LLC (“Nasdaq”) indicating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) due to our failure to
maintain a minimum of $2,500,000 in shareholders’ equity (the “Minimum Shareholders’ Equity Requirement”) or
any alternatives to such requirement. In order to maintain our listing on the Nasdaq Capital Market, we submitted a plan of compliance
addressing how we intended to regain compliance.
On
March 27, 2024, we received a delist determination letter from Nasdaq advising us that the Staff had determined to delist our
securities from Nasdaq due to non-compliance with the Minimum Shareholders’ Equity Requirement, unless we timely request a hearing
before the Nasdaq Hearings Panel (the “Panel”). We timely requested a hearing before the Panel. On June 10, 2024, the Panel
granted our request for continued listing subject to us evidencing compliance with the Equity Rule by August 30, 2024. There can be no
assurance that we will be able to timely demonstrate such compliance with the
Equity Rule.
In
addition, on May 20, 2024, the Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that it was not in compliance with
the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), which requires the Company’s common stock to maintain
a minimum bid price of $1.00 per share. On June 20, 2024, the Company received a letter from Nasdaq that, for the 10 consecutive business
days from June 5, 2024 to June 28, 2024, the closing bid price of the Company’s common stock had been at $1.00 per share or greater.
Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency
matter now closed.
THE
OFFERING
Shares
of common stock currently outstanding |
|
6,016,326
shares of common stock. |
|
|
|
Securities
offered by the selling stockholders |
|
Up
to 2,069,317 shares of the Company’s common stock, par value $0.0001 per share, consisting of: (i) 1,999,340 shares of our
common stock issuable upon the exercise of the July 2024 Warrants, and (ii) 69,977 shares of our common stock issuable upon the exercise
of the July 2024 Placement Agent Warrants. |
|
|
|
Shares
of common stock to be outstanding assuming exercise of the warrants |
|
8,085,643
shares of common stock. |
|
|
|
Selling
Stockholders |
|
All
of the shares of our common stock are being offered by the selling stockholders. See “Selling Stockholder” on page 7
of this prospectus for more information on the selling stockholders. |
|
|
|
Plan
of Distribution |
|
The
selling stockholders will determine when and how they will sell the common stock covered by this prospectus. See the “Plan
of Distribution” section of this prospectus. |
|
|
|
Use
of Proceeds |
|
We
will not receive any proceeds from the sale of the Common Stock by the selling stockholders. All net proceeds from the sale of the
Common Stock covered by this prospectus will go to the selling stockholders. However, we may receive the proceeds from any exercise
of warrants if the selling stockholders do not exercise their warrants on a cashless basis, if and when exercised. See the section
of this prospectus titled “Use of Proceeds.” |
|
|
|
Risk
Factors |
|
See
“Risk Factors” and other information appearing elsewhere in this prospectus for a discussion of factors you should carefully
consider before deciding whether to invest in our securities. |
|
|
|
Listings |
|
Our
common stock is listed on the Nasdaq Capital Market under the symbol “ASNS”. |
Unless
otherwise indicated, all information in this prospectus (i) assumes no exercise of the outstanding warrants described above, and (ii)
gives retroactive effect to the 1-for-10 reverse stock split effected on April 19, 2023.
Corporate
Information
We
were incorporated in Delaware in 1998. We completed our initial public offering on May 17, 2022 and our common stock is currently listed
on the Nasdaq Global Select Market under the symbol “ASNS.” Our principal executive offices are located at 4039 Clipper Court,
Fremont, CA 94538, and our telephone number is (510)-545-1040. The information contained on our website and available through our website
is not incorporated by reference into and should not be considered a part of this prospectus, and the reference to our website in this
prospectus is an inactive textual reference only.
RISK
FACTORS
An
investment in our securities involves a high degree of risk. You should carefully consider the risk factors set forth in our most recent
Annual Report on Form 10-K on file with the SEC, which is incorporated by reference into this prospectus, as well as the following risk
factors, which supplement or augment the risk factors set forth in our Annual Report on Form 10-K. Before making an investment decision,
you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. The
risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating
results and financial condition and could result in a complete loss of your investment.
Sales
of substantial amounts of our Common Stock by a selling stockholder, or the perception that these sales could occur, could adversely
affect the price of our Common Stock.
The
sale by the selling stockholders of a significant number of shares of Common Stock could have a material adverse effect on the market
price of our Common Stock. In addition, the perception in the public markets that the selling stockholder may sell all or a portion of
its shares as a result of the registration of such shares for resale pursuant to this prospectus could also in and of itself have a material
adverse effect on the market price of our Common Stock. We cannot predict the effect, if any, that market sales of those shares of Common
Stock or the availability of those shares of Common Stock for sale will have on the market price of our Common Stock.
USE
OF PROCEEDS
We
are not selling any Common Stock under this Prospectus and we will not receive any proceeds from the sale of the Common Stock by the
selling stockholders. All net proceeds from the sale of the Common Stock covered by this prospectus will go to the selling stockholders.
We expect that the selling stockholders will sell their Common Stock as described under “Plan of Distribution.”
We
may receive proceeds from the exercise of the warrants to the extent that these warrants are exercised for cash by the selling stockholders.
Warrants, however, are exercisable on a cashless basis under certain circumstances. If all of the warrants mentioned above were exercised
for cash in full, the gross proceeds would be approximately $3.7 million. We intend to use the net proceeds of such warrant exercise,
if any, for general corporate purposes. Pending such uses, we intend to invest the net proceeds in bank deposits. We can make no assurances
that any of the warrants will be exercised, or if exercised, that they will be exercised for cash, the quantity which will be exercised
or in the period in which they will be exercised.
SELLING
STOCKHOLDERS
The
shares of common stock being offered by the selling stockholders are those shares of common stock issuable upon exercise of the July
2024 Warrants and July 2024 Placement Agent Warrants previously issued in connection with the Warrant Inducement. For additional information
regarding the issuance of those shares of common stock and warrants, see “Prospectus Summary — Recent Developments —
Warrant Inducement” above. We are registering the shares of common stock in order to permit the selling stockholders to offer the
shares of common stock for resale from time to time. Other than with respect to the Placement Agent, which acted as our placement agent
in the July 2024 Warrant Inducement, the June 2024 Warrant Inducement, and in each of our December 2023 and May 2023 financings, except
for the ownership of the warrants issued to the Placement Agent, and the shares of common stock issued and issuable pursuant to prior
financings, the selling stockholders have not had any material relationship with us within the past three years.
The
table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by
each of the selling stockholders. The second column lists the number the shares of common stock beneficially owned by each selling stockholder,
based on its ownership of the shares of common stock, including shares underlying the July 2024 Warrants or Placement Agent Warrants,
as of July 20, 2024, assuming exercise of the July 2024 Warrants or the July 2024 Placement Agent Warrants held by the selling stockholders
on that date, without regard to any limitations on conversions or exercises. The third column lists the maximum number of the shares
of common stock being offered in this prospectus by the selling stockholders. The fourth and fifth columns list the amount of the shares
of common stock owned after the offering, by number of the shares of common stock and percentage of outstanding the shares of common
stock (assuming for the purpose of such percentage, 6,016,326 shares outstanding as of July 20, 2024) assuming in both cases the sale
of all of the shares of common stock offered by the selling stockholders pursuant to this prospectus, and without regard to any limitations
on conversions or exercises.
Under
the terms of the July 2024 Warrants and the July 2024 Placement Agent Warrants issued in the July 2024 Warrant Inducement, a selling
stockholder may not exercise the warrants to the extent such exercise would cause such selling stockholder, together with its affiliates,
to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding shares
of common stock following such exercise, excluding for purposes of such determination shares of common stock not yet issuable upon exercise
of the warrants and placement agent warrants which have not been exercised. The number of shares does not reflect this limitation. The
selling stockholders may sell all, some or none of their shares of common stock or July 2024 Warrants or the July 2024 Placement Agent
Warrants in this offering. See “Plan of Distribution.”
Name of selling stockholder | |
Number of Shares of Common Stock Owned Prior to Offering | | |
Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus | | |
Shares Beneficially Owned After Offering | |
| |
| | |
| | |
Number | | |
Percentage | |
Armistice Capital, LLC(1) | |
| 4,542,197 | (2) | |
| 1,999,340 | (3) | |
| - | (4) | |
| * | |
Michael Vasinkevich(5) | |
| 189,208 | (6) | |
| 44,872 | (7) | |
| 144,336 | (8) | |
| * | |
Noam Rubinstein(5) | |
| 92,946 | (9) | |
| 22,043 | (10) | |
| 70,903 | (11) | |
| * | |
Craig Schwabe(5) | |
| 9,956 | (12) | |
| 2,362 | (13) | |
| 7,597 | (14) | |
| * | |
Charles Worthman(5) | |
| 2,951 | (15) | |
| 700 | (16) | |
| 2,251 | (17) | |
| * | |
(1) |
The
securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the “Master Fund”),and
may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (“Armistice Capital”), as the investment manager
of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The warrants are subject to a beneficial
ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the warrants
that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess
of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison
Avenue, 7th Floor, New York, NY 10022. |
(2) |
Consists
of (i)1,271,187 shares of common stock issuable upon the exercise of warrants issued in December 2023, (ii) 999,670 shares of common
stock issuable upon the exercise of the June 2024 Warrants issued in connection with the June 2024 Warrant Inducement; and (iii)
1,999,340 shares of common stock issuable upon exercise of the July 2024 Warrants issued in connection with the July 2024 Warrant
Inducement. All of these warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restrict the Master
Fund from exercising that portion of the warrants that would result in the Master Fund and its affiliates owning, after exercise,
a number of shares of common stock in excess of the beneficial ownership limitation. |
|
|
(3) |
Consists
of 1,999,340 shares of common stock issuable upon the exercise of the July 2024 Warrants issued in connection with the July 2024
Warrant Inducement. |
(4) |
Does
not include (i) 1,271,187 shares of common stock issuable upon the exercise of warrants issued in December 2023, and (ii) 999,670
shares of common stock issuable upon the exercise of the June 2024 Warrants issued in connection with the June 2024 Warrant Inducement. All
of these warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restrict the Master Fund from
exercising that portion of the warrants that would result in the Master Fund and its affiliates owning, after exercise, a number
of shares of common stock in excess of the beneficial ownership limitation. |
(5) |
Each
of the selling stockholders is affiliated with H.C. Wainwright & Co., LLC, a registered broker dealer with a registered address
of H.C. Wainwright & Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole voting and dispositive power over the
securities held. The number of shares beneficially owned prior to this offering consist of shares of common stock issuable upon exercise
of placement agent warrants, which were received as compensation. The selling stockholder acquired the placement agent warrants in
the ordinary course of business and, at the time the placement agent warrants were acquired, the selling stockholder had no agreement
or understanding, directly or indirectly, with any person to distribute such securities. |
|
|
(6) |
Consists
of (i) 42,404 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 57,060 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement, (iii) 44,872 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement, and (iv) 44,872 shares of common stock issuable upon exercise of Placement Agent
Warrants issued in connection with the July 2024 Warrant Inducement. |
(7) |
Consists
of 44,872 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the July 2024 Warrant
Inducement. |
(8) |
Consists
of (i) 42,404 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 57,060 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement; and (iii) 44,872 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement. |
(9) |
Consists
of (i) 20,830 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 28,030 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement, (iii) 22,043 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement, and (iv) 22,043 shares of common stock issuable upon exercise of Placement Agent Warrants
issued in connection with the July 2024 Warrant Inducement. |
(10) |
Consists
of 22,043 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the July 2024 Warrant
Inducement. |
(11) |
Consists
of (i) 20,830 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 28,030 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement, and (iii) 22,043 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement. |
(12) |
Consists
of (i) 2,232 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 3,003 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement, and (iii) 2,362 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement, and (iv) 2,362 shares of common stock issuable upon exercise of Placement Agent Warrants issued
in connection with the July 2024 Warrant Inducement. |
|
|
(13) |
Consists
of 2,362 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the July 2024 Warrant
Inducement. |
|
|
(14) |
Consists
of (i) 2,232 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 3,003 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement, and (iii) 2,362 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement. |
|
|
(15) |
Consists
of (i) 661 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 890 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement, (iii) 700 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement, and (iv) 700 shares of common stock issuable upon exercise of Placement Agent Warrants issued
in connection with the July 2024 Warrant Inducement |
|
|
(16) |
Consists
of 700 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the July 2024 Warrant
Inducement. |
|
|
(17) |
Consists
of (i) 661 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the May 2023 Private
Placement, (ii) 890 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection with the December
2023 Private Placement, and (iv) 700 shares of common stock issuable upon exercise of Placement Agent Warrants issued in connection
with the June 2024 Warrant Inducement. |
DESCRIPTION
OF OFFERED SECURITIES
The
following description is intended as a summary of our Charter and our Bylaws, each of which will become effective prior to the effectiveness
of the registration statement of which this prospectus forms a part, and which will be filed as exhibits to the registration statement
of which this prospectus forms a part, and to the applicable provisions of the DGCL. Because the following is only a summary, it does
not contain all of the information that may be important to you. For a complete description, you should refer to our Charter and Bylaws.
The
selling stockholders may, from time to time, sell, transfer, or otherwise dispose of any or all of their shares of common stock or interests
in shares of common stock on any stock exchange, market, or trading facility on which the shares are traded or in private transactions
at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices
determined at the time of sale, or at negotiated prices. This prospectus provides you with a general description of the common stock
the selling stockholders may offer.
Authorized
Capital Stock
Our
Charter authorizes us to issue up to 42,803,774 shares consisting of 30,000,000 shares of common stock with a par value of
US$0.0001 per share, 2,803,774 shares of non-voting common stock with a par value of US$0.0001 per share and 10,000,000 shares
of preferred stock with a par value of US$0.0001 per share. As of July 24, 2024, there were 52 holders of record of our common stock.
Common
Stock
The
shares of our common stock have the following rights, preferences and privileges:
Voting
Rights
Each
holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders.
Any action at a meeting at which a quorum is present will be decided by a majority of the voting power present in person or represented
by proxy, except in the case of any election of directors, which will be decided by a plurality of votes cast. There is no cumulative
voting.
Dividend
Rights
Holders
of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available
for payment, subject to the rights of holders, if any, of any class of stock having preference over the common stock. Any decision to
pay dividends on our common stock will be at the discretion of our board of directors. Our board of directors may or may not determine
to declare dividends in the future. See “Dividend Policy.” The board’s determination to issue dividends will depend
upon our profitability and financial condition any contractual restrictions, restrictions imposed by applicable law and the SEC, and
other factors that our board of directors deems relevant.
Liquidation
Rights
In
the event of a voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of our common stock will be
entitled to share ratably on the basis of the number of shares held in any of the assets available for distribution after we have paid
in full, or provided for payment of, all of our debts and after the holders of all outstanding series of any class of stock have preference
over the common stock, if any, have received their liquidation preferences in full.
Other
Rights and Preferences
Upon
the closing of this offering, holders of our common stock will have no pre-emptive, conversion, subscription or other rights, and there
are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of
our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock
that we may designate in the future. Upon the closing of this offering, shares of our common stock are not convertible into shares of
any other class of capital stock, nor are they subject to any redemption or sinking fund provisions.
Fully
paid and nonassessable
All
of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable.
Preferred
stock
We
are authorized to issue up to 10,000,000 shares of preferred stock. Our Charter authorizes the board to issue these shares in one
or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights
and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights
(including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number
of shares constituting the series. Our board of directors could, without stockholder approval, issue preferred stock with voting and
other rights that could adversely affect the voting power and other rights of the holders of common stock and which could have the effect
of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority of
our outstanding voting stock. Upon the closing of this offering, no shares of preferred stock will be outstanding.
Charter
and Bylaw Provisions
Charter
and Bylaw Provisions
Our
Charter and our Bylaws to be effective upon the closing of this offering, include a number of provisions that could deter hostile takeovers
or delay or prevent changes in control of our management team, including the following:
|
● |
Board
of Directors vacancies. Our Charter to be effective upon the closing of this offering, provides that vacancies on the board of
directors may be filled only by the affirmative vote of a majority of the directors then in office, irrespective of whether there
is a quorum, or by a sole remaining director. Additionally, the number of directors to serve on our board of directors is fixed solely
and exclusively by resolution duly adopted by our board of directors. This would prevent a stockholder from increasing the size of
our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees.
This makes it more difficult to change the composition of our board of directors but promotes continuity of management. |
|
● |
Classified
Board of Directors. In accordance with our Charter, as it will be in effect following the effectiveness of the registration statement
of which this prospectus forms a part, our board of directors will be divided into three classes with staggered three-year terms.
At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from
the time of election and qualification until the third annual meeting following election. Our directors will be divided among the
three classes. We expect that any additional directorships resulting from an increase in the number of directors will be distributed
among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division
of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management
or a change in control. |
|
● |
Special
Meetings of Stockholders. Our Bylaws to be effective upon the closing of this offering, provides that special meetings of our
stockholders may be called by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority
of the directors then in office, and special meetings of stockholders may not be called by any other person or persons. |
|
● |
No
Cumulative Voting. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors
unless the corporation’s certificate of incorporation provides otherwise. Our Charter does not provide for cumulative voting. |
|
● |
Amendment
of Charter and Bylaw Provisions. Any amendment of our Charter requires the affirmative vote of the majority of the outstanding
shares of capital stock entitled to vote on such amendment, and the affirmative vote of the majority of the outstanding shares of
each class entitled to vote thereon as a class, except that the provision in the Charter regarding the staggered board may not be
repealed or amended without the vote of the holders of not less than 80% of the Company’s voting stock, voting as a single
class. Amendments to our Bylaws may be executed pursuant to a resolution by the Board of Directors pursuant to an affirmative vote
of a majority of the directors then in office, or by the affirmative vote of at least 75% of the outstanding shares of capital stock
entitled to vote. |
|
● |
Delaware
Business Combination Statute. The Company is subject to the “business combination” provisions of Section 203
of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination
with an interested stockholder for a period of three years following the date such person becomes an interested stockholder,
unless the business combination or the transaction in which such person becomes an interested stockholder is approved in a prescribed
manner. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in
a financial benefit to the interested stockholder. Generally, an “interested stockholder” is a person that, together
with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did
own, 15% or more of a corporation’s voting stock. The existence of this provision may have an anti-takeover effect with respect
to transactions not approved in advance by our Board of Directors, and the anti-takeover effect includes discouraging attempts that
might result in a premium over the market price for the shares of our common stock. |
|
● |
Exclusive
Forum. Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware
is the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting
a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, stockholder or other employees to
us or our stockholders, (iii) any action asserting a claim against the Corporation or any current or former director, officer,
stockholder, employee or agent of the Corporation arising pursuant to any provision of the DGCL, our Charter or our Bylaws, (iv) any
action to interpret, apply, enforce or determine the validity of the Company’s Charter or Bylaws, (v) any action asserting
a claim against us governed by the internal affairs doctrine or (vi) any action asserting an “internal corporate claim”
as that term is defined in Section 115 of the General Corporation Law. The federal district courts of the United States
of America shall be the exclusive forum for the resolution of any complaint, claim or proceeding asserting a cause of action arising
under the Exchange Act or the Securities Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction
for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and
regulations thereunder. Stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder.
Any person or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock shall be deemed to
have notice of and consented to the forum provision in our Charter. This choice of forum provision may limit a stockholder’s
ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees,
which may discourage such lawsuits against us and our directors, officers and other employees. |
Anti-Takeover Provisions
The
provisions of the DGCL, our Charter and our Bylaws may have the effect of delaying, deferring or discouraging another person from acquiring
control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also
designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that
the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages
of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.
Our
Charter established a classified board of directors, divided in three classes with staggered three-year terms. Under the classified
board of directors structure, only one class of directors would be elected at each annual meeting of our stockholders, with the other
classes continuing for the remainder for their respective three-year terms. Under the classified board of directors structure: (i) directors
in Class I, consisting of Gideon Marks, are to stand for election at the Annual Meeting to be held in 2026; (ii) directors
in Class II, consisting of Joseph Moscovitz, are to stand for election at the annual meeting of stockholders to be held in 2024;
and (iii) directors in Class III, consisting of Israel Niv and Tuvia Barlev, are to stand for election at the annual meeting
of stockholders to be held in 2025.
Limitations
on Liability, Indemnification of officers and directors and insurance
Our
Charter and Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted
by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach
of fiduciary duties as directors, except liability for:
|
● |
any
breach of the director’s duty of loyalty to us or our stockholders; |
|
● |
any
act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
|
● |
unlawful
payments of dividends or unlawful stock repurchases, or redemptions as provided in Section 174 of the DGCL; or |
|
● |
any
transaction from which the director derived an improper personal benefit. |
Listing
Our
common stock is listed on the Nasdaq Capital Market under the symbol “ASNS”.
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock will be VStock Transfer, LLC. The transfer agent and registrar’s address
is 18 Lafayette Place, Woodmere, NY 11598.
Exclusive
Forum
Our
Charter provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware
will be the sole and exclusive forum for any stockholder for (a) any derivative action or proceeding brought on our behalf, (b) any
action asserting a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any current or former director, officer, stockholder,
employee or agent of the Company to the Company or the Company’s stockholders, (c) any action asserting a claim against the
Corporation or any current or former director, officer, stockholder, employee or agent of the Corporation arising pursuant to any provision
of the DGCL or the Company’s Certificate of Incorporation or Bylaws, (d) any action to interpret, apply, enforce or determine
the validity of the Company’s Certificate of Incorporation or Bylaws, or (e) any action asserting a claim governed by the
internal affairs doctrine or (f) any action asserting an “internal corporate claim” as that term is defined in Section 115
of the General Corporation Law. The federal district courts of the United States of America shall be the exclusive forum for the
resolution of any complaint, claim or proceeding asserting a cause of action arising under the Exchange Act or the Securities Act.
Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought
to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.
Stockholders
cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or
otherwise acquiring or holding any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum
provision in our Charter.
The
choice-of-forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for
disputes with the Company or its directors, officers or other employees, and may result in increased costs to a stockholder who has to
bring a claim in a forum that is not convenient to the stockholder, which may discourage such lawsuits. Although under Section 115
of the DGCL, exclusive forum provisions may be included in a company’s certificate of incorporation, the enforceability of similar
forum provisions in other companies’ certificates or incorporation or bylaws has been challenged in legal proceedings, and it is
possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive
forum provision of our Charter inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings,
we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect
our business, financial condition and results of operations and result in a diversion of the time and resources of our management and
board of directors.
Anti-Takeover Provisions
of the DGCL and Charter Provisions
Certain
provisions of the DGCL and certain provisions included in our Charter and Bylaws summarized below may be deemed to have an anti-takeover effect
and may delay, deter, or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including
attempts that might result in a premium being paid over the market price for the shares held by stockholders.
Removal
of Directors
Our
Bylaws provide that stockholders may only remove a director with or without cause by a vote of no less than a majority of the shares
present in person or by proxy at the meeting and entitled to vote, voting together as a single class.
Amendments
to Certificate of Incorporation
Certain
sections of our Certificate of Incorporation require the affirmative vote of the holders of a majority of the voting power of the then
outstanding shares of capital stock of the Company entitled to vote, voting together as a single class, except that the provision in
the Charter regarding the staggered board may not be repealed or amended without the vote of the holders of not less than 80% of the
Company’s voting stock, voting as a single class.
Staggered
Board
The
board of directors is divided into three classes, with regular three-year staggered terms. This classification system increases
the difficulty of replacing a majority of the directors and may tend to discourage a third-party from making a tender offer or otherwise
attempting to gain control of the Company. In addition, under Delaware law, the Certificate and the By-Laws, the Company’s directors
may be removed from office by the stockholders only for cause and only in the manner provided for in the Certificate. These factors may
maintain the incumbency of the board of directors.
Amendments
to Bylaws
Our
Charter limits the abilities of the directors and stockholders to amend our Bylaws in certain circumstances. In particular, the Bylaws
may be amended only by the vote of a majority of all of the directors then in office, or by the affirmative vote of the stockholders
holding at least 75% of the outstanding shares of capital stock entitled to vote in accordance with the provisions of the Charter, Bylaws,
and the DGCL.
No
Cumulative Voting
Our
Charter does not provide for cumulative voting.
Special
Meetings of Stockholders
Our
Bylaws provide that, except as otherwise required by law, special meetings of the stockholders may be called only by an officer at the
request of a majority of our board of directors, by our Chief Executive Officer or President or by the holders of not less than 25% of
the holders of stock entitled to vote at the meeting.
Stockholders
Agreement
We
are party to the Amended and Restated Stockholders Agreement, dated February 2, 2016, or the Stockholders Agreement, pursuant to which
certain holders of our common stock have the right to demand that we file a registration statement or request that their common stock
be covered by a registration statement that we are otherwise filing. All rights under the Stockholders Agreement will terminate upon
the closing of this offering.
PLAN
OF DISTRIBUTION
The
selling stockholders of the Shares and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or
all of their securities covered hereby on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which
the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may
use any one or more of the following methods when selling securities:
|
● |
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
|
● |
block
trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
as principal to facilitate the transaction; |
|
● |
purchases
by a broker-dealer as principal and resale by the broker-dealer for its account; |
|
● |
an
exchange distribution in accordance with the rules of the applicable exchange; |
|
● |
privately
negotiated transactions; |
|
● |
settlement
of short sales; |
|
● |
in
transactions through broker-dealers that agree with the selling stockholder to sell a specified number of such securities at a stipulated
price per security; |
|
● |
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
|
● |
a
combination of any such methods of sale; or |
|
● |
any
other method permitted pursuant to applicable law. |
The
selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act,
if available, rather than under this prospectus.
Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from each selling stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup
or markdown in compliance with FINRA Rule 2121.
In
connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The selling stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The
selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. The selling stockholders have informed us that they do not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.
The
resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws.
In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in
Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing
of purchases and sales of the common stock by the selling stockholder or any other person. We will make copies of this prospectus available
to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to
the time of the sale (including by compliance with Rule 172 under the Securities Act).
LEGAL
MATTERS
The
validity of the shares of the common stock offered by this prospectus will be passed upon for us by Pearl Cohen Zedek Latzer Baratz LLP,
New York, NY. Certain legal matters in connection with this offering relating to U.S. law will be passed upon for us by Greenberg Traurig,
LLP, New York, NY.
EXPERTS
The
financial statements incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2023
have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company’s ability to continue
as a going concern as described in Note 1b to the financial statements) of Kesselman & Kesselman, Certified Public Accountants (Isr.),
a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority
of said firm as experts in auditing and accounting.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed a registration statement on Form S-1 with the SEC under the Securities Act with respect to the securities offered
in this prospectus. This prospectus, which is filed as part of a registration statement, does not contain all of the information set
forth in the registration statement, some portions of which have been omitted in accordance with the SEC’s rules and regulations.
Statements made in this prospectus as to the contents of any contract, agreement or other document referred to in this prospectus are
not necessarily complete and are qualified in their entirety by reference to each such contract, agreement or other document that is
filed as an exhibit to the registration statement.
You
can read our SEC filings, including the registration statement, over the internet at the SEC’s website. Upon completion of this
offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements
and other information with the SEC. The SEC’s website contains reports, proxy and information statements and other information
regarding registrants that file electronically with the SEC. The address of that site is http://www.sec.gov.
We
also maintain a website at www.Actelis.com, at which you may access these materials free of charge as soon as reasonably practicable
after they are electronically filed with, or furnished to, the SEC.
However,
the information contained in or accessible through our website is not part of this prospectus or the registration statement of which
this prospectus forms a part, and investors should not rely on such information in making a decision to purchase our common stock in
this offering.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information into this prospectus. This means that we can disclose important information
to you by referring you to another document filed separately with the SEC. The information that we incorporate by reference is considered
to be part of this prospectus. Because we are incorporating by reference our future filings with the SEC, this prospectus is continually
updated and those future filings may modify or supersede some or all of the information included or incorporated in this prospectus.
This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this
prospectus or in any document previously incorporated by reference have been modified or superseded.
This
prospectus incorporates by reference the documents listed below that have been previously filed with the SEC:
|
● |
our
Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 26, 2024; |
|
● |
our
Quarterly Report on Form 10-Q for quarter ended March 31, 2024 filed with the SEC on May 14, 2024; |
|
● |
our
Current Reports on Form 8-K filed with the SEC on January
8, 2024, February 12,
2024, February 14, 2024, March
14, 2024, June 6, 2024, June
14, 2024, June 18,
2024, June 20, 2024, June
28, 2024, July 2, 2024, July
24, 2024, July 30, 2024 and August 2, 2024; |
|
● |
the
description of our common stock, which is contained in the registration statement on Form 8-A filed with the SEC on May 4, 2022 (File
No. 001-41375). |
We
also incorporate by reference all future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act, subsequent to the date of this prospectus
and prior to the termination of the offering.
You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide
you with different information. Any statement contained in a document incorporated by reference into this prospectus will be deemed to
be modified or superseded for the purposes of this prospectus to the extent that a later statement contained in this prospectus or in
any other document incorporated by reference into this prospectus modifies or supersedes the earlier statement. Any statement so modified
or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should not assume
that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents
incorporated by reference in this prospectus.
The information about us contained
in this prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of
any or all of these filings, at no cost, by writing or telephoning us at Yoav Efron, Chief Financial Officer and Deputy Chief Executive
Officer, 4039 Clipper Court, Fremont, CA 94538 USA, telephone number +1-510-545-1045 or by emailing us at yoave@actelis.com.
Actelis
Networks, Inc.
PRELIMINARY
PROSPECTUS
August 7, 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
From Aug 2023 to Aug 2024